Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: Systematic review and meta-analysis;Eficaciay seguridad de la vacuna contra el virus de papiloma humano para la prevención del cáncer de cuello uterino: Revisión sistemática y metaanálisis

Archivos Argentinos de Pediatria

Volumn 110, Issue 6, 2012, Pages 483-489

  Rey Ares, Lucila ^a   Ciapponi, Agustín ^a,b   Pichon Riviere, Andrés ^a,c  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Female; Papillomavirus vaccines; Systematic review and meta analysis; Uterine cervical neoplasm; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

EID: 84871382677     PISSN: 03250075     EISSN: 16683501     Source Type: Journal    
DOI: 10.5546/aap.2012.483     Document Type: Article

References (27)

1. WHO. GLOBOCAN. Lyon, France: World Health Organization; 2008 [Acceso: 10 de junio de 2011]. Disponible en: http://globocan.iarc.fr/.
2. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976;36(2 pt 2):794.
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5A):3-8. (Pubitemid 127695953)
4. Bosch FX, Manos MM, Munoz N, Sherman M, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802.
5. Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis. PLoS ONE 2011;6(10):e25493.
6. UNICEF. Immunization Summary, A statistical reference containing data through 2009. New York, USA: World Health Organization; 2011. [Acceso: 7 de julio de 2012]. Disponible en: http://www.childinfo.org/files/32775-UNICEF.pdf.
7. Sawaya GF, Smith-McCune K. HPV vaccination - more answers, more questions. N Engl J Med 2007;356(19):1991-3. (Pubitemid 46740311)
8. Miller NB, Raychaudhuri G, Toerner JG. Human papillomavirus vaccine. N Engl J Med 2007;357(11):1154-5; author reply 5-6.
9. ASCUS-LSIL, Traige, Study, (ALTS), Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188(6):1383-92.
10. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5):569-78. (Pubitemid 39473185)
11. Wright TC, Jr., Cox JT, Massad LS, Carlson J, et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003;189(1):295-304. (Pubitemid 36886564)
12. Paavonen J, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14.
13. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199(7):936-44.
14. Harper DM, Franco EL, Wheeler CM, Moscicki AB, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247-55.
15. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102(5):325-39.
16. Garland SM, Hernández-Avila M, Wheeler CM, Pérez G, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19):1928-43. (Pubitemid 46740303)
17. Future, II, Study, Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.
18. Goldie SJ, O'Shea M, Díaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reproduct Health Matters 2008;16(32):86-96.
19. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007;25(33):6257-70. (Pubitemid 47088030)
20. Goldie SJ, Díaz M, Constenla D, Alvis N, et al. Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine 2008;26(Suppl. 11):L59-L72.
21. Colantonio L, Gómez JA, Demarteau N, Standaert B, et al. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009;27(40):5519-29.
22. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, de la Rosa AP, Witlen R. Relación costo-efectividad de las intervenciones preventivas contra el cáncer cervical en mujeres mexicanas: resultados de un modelo markoviano desde la perspectiva del sector público. Sal Publ Mex 2008;50(2):107-18.
23. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 2007;26(1):128-39. (Pubitemid 350218187)
24. Reynales-Shigematsu LM, Rodrígues ER, Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009; 40(6):503-13.
25. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97(9):1322-8. (Pubitemid 350035812)
26. De La Hoz F, Alvis N, Narvez J, Gamboa O, Chocont A. Cost-effectiveness of human papillomavirus vaccine in Colombia in 2007. Value Health 2009;12 (3):A42.
27. Demarteau N, Suárez E, Gómez J, Standaert B. Modelling the impact of different vaccine profiles on the cost-effectiveness of HPV vaccination in the Chilean setting. Int J Gyn Obst 2009;107:S673-S4.